The PrEPWatch Resource Database offers a wide range of material on the status of PrEP as an option for biomedical HIV prevention around the world. Search this database to find step-by-step guidance for rolling out PrEP, summaries of the research to date on safety, efficacy and implementation, tools to assist planning and roll out, country updates on PrEP policy and access, and lessons learned from those efforts.
Showing results 11 - 20 of 25
Use of the Dapivirine vaginal ring and effect on cervical cytology abnormalities
This study aims to determine if the dapivirine vaginal ring and the ring device alone (flexible silicone matrix polymer) was associated with the development of cervical cytology abnormalities.
Research, Service Delivery
The HIV Prevention Trials Network (HPTN) hosted a community webinar to discuss the primary results of HPTN 084, a randomized, double-blind controlled trial designed to evaluate the efficacy and safety of long-acting injectable cabotegravir (CAB LA) to prevent the sexual acquisition of HIV in cisgender women in sub-Saharan Africa.
Vaginal Ring Acceptability and Related Preferences among Women in Low- and Middle-income Countries: A systematic review and narrative synthesis
The vaginal ring (VR) is a female-initiated drug-delivery platform used for different indications, including HIV pre-exposure prophylaxis (PrEP). This article outlines a systematic review of VR acceptability, values and preferences among women in low- and middle-income countries (LMIC) to inform further investment and/or guidance on VR use for HIV prevention.
HOPE Protocol Team Meeting Lessons Learned from PrEP Rollout for the Dapivirine Ring
This presentation outlines lessons from oral PrEP demonstration projects that could be applied to the rollout of the dapivirine vaginal ring as well as plans for ring introduction.
Results of open-label study of a vaginal ring for HIV prevention suggest women are interested in and willing to use it
This article from the Microbicide Trials Network shares the results of an open-label study of a vaginal ring for HIV prevention
Community/Advocacy, Demand Creation/Marketing, Research
Adherence to the Dapivirine vaginal ring and oral PrEP among adolescent girls and young women in Africa: interim results from the REACH study
Adolescent girls and young women (AGYW) account for most new HIV infections in sub-Saharan Africa. WHO has endorsed oral PrEP and dapivirine vaginal ring (ring) for women at substantial risk of HIV infection. However, adherence to both products was lower among younger women in randomized placebo-controlled trials. The authors of this article assessed interim safety,…
Microbicide Trials Network-042 – DELIVER Study
Microbicide Trials Network-042/DELIVER is a Phase IIIb open-label study designed to evaluate the safety and acceptability of the monthly dapivirine vaginal ring and oral PrEP in pregnant women.
What is the dapivirine ring? How does it work? Is it safe to use? These are all questions that this Dapivirine Ring backgrounder by the International Partnership for Microbicides (IPM) answers.
Barriers to Provision HIV Biomedical Prevention Services in sub-Saharan Africa
AVAC conducted a desk review of the HIV prevention policy landscape in eight countries in sub-Saharan Africa. This analysis includes: training requirements for provision of PrEP and contraceptives; clinical guidelines; National Strategic Plans for HIV and Sexual and Reproductive Health; implementation strategies; national policies on age of consent and the criminality of same-sex relationships; in-depth…
Research, Normative Guidance/Policies
Prevention Market Manager Project Summary
The Prevention Market Manager (PMM) is a collaboration between AVAC and the Clinton Health Access Initiative, funded by the Bill & Melinda Gates Foundation. This summary document provides a brief overview of PMM's goals, accomplishments, and learnings.
Research, Service Delivery